LeMaitre Vascular (NASDAQ:LMAT) Issues Q1 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.480-0.530 for the period, compared to the consensus EPS estimate of 0.510. The company issued revenue guidance of $56.7 million-$58.7 million, compared to the consensus revenue estimate of $58.1 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.150-2.320 EPS.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $3.14 during trading on Thursday, hitting $99.91. The company’s stock had a trading volume of 197,639 shares, compared to its average volume of 138,669. The stock’s 50-day moving average price is $96.75 and its two-hundred day moving average price is $94.62. LeMaitre Vascular has a fifty-two week low of $62.39 and a fifty-two week high of $109.58. The company has a market capitalization of $2.25 billion, a PE ratio of 54.60, a PEG ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LMAT. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Barrington Research lifted their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average target price of $94.63.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.